<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000045398"><TermName>triacetyluridine</TermName><TermPronunciation>(try-A-seh-til-YOOR-ih-deen)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied for its ability to protect against the gastrointestinal side effects caused by fluorouracil. It belongs to the family of drugs called cytoprotective agents. Also called PN401.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000705415" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;triacetyluridine&quot;" language="en" id="_3"/><MediaLink ref="CDR0000705414" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;triacetiluridina&quot;" language="es" id="_4"/><SpanishTermName>triacetiluridina</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio por su capacidad de protección contra los efectos secundarios del fluorouracilo sobre el aparato digestivo. Es un tipo de citoprotector. También se llama PN401.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateLastModified>2006-10-30</DateLastModified></GlossaryTerm>
